本组肝癌病人移植术后3 年无复发生存率为100 ％ 。

The recurrence - free survivalrate at 3 years was 100 % .

youdao

研究者同时发现有28%的患者被预测为对治疗敏感，他们的3年无远处复发生存率为92%，绝对危险度大幅下降18%。

They also observed that in 28% of patients predicted to be sensitive to treatment, 3-year distant relapse-free survival (DRFS) was 92%, with a significant absolute risk reduction of 18%.

youdao

在治疗的第3年，雌激素受体阳性患者获得97%的无远处复发生存率，绝对危险度大幅下降11%。

At 3 years, ER-positive patients achieved a DRFS of 97% and a significant absolute risk reduction of 11%.

youdao